Risk of prostate cancer in lynch syndrome: A systematic review and meta-Analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 3, 2014, Pages 437-449

  Ryan, Shae ^a   Jenkins, Mark A ^a   Win, Aung Ko ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; META ANALYSIS; MISMATCH REPAIR; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; COMPLICATION; GENETICS; PROSTATIC NEOPLASMS;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84896528910     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1165     Document Type: Review

References (55)

1. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-9.
2. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258-61.
3. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
4. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-2.
5. Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997;57:3920-3.
6. Nicolaides NC, Papadopoulos N, Liu B, Weit Y-F, Carter KC, Ruben SM, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
7. Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau H, van Puijenbroek M, Tops C, et al. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology 2006;130:312-22.
8. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 30 exons of TACSTD1. Nat Genet 2009;41:112-7.
9. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009; 30:197-203.
10. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer 2005;4:233-7.
11. Dunlop MG, FarringtonSM, Nicholl I, Aaltonen L, Petersen G, Porteous M, et al. Population carrier frequency ofhMSH2 and hMLH1 mutations. Br J Cancer 2000;83:1643-5.
12. Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res 2011;4:1-5.
13. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305: 2304-10.
14. Win AK, Young JP, Lindor NM, Tucker K, Ahnen D, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30:958-64.
15. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 andMSH2 mutation carriers. Hum Mutat 2013;34:490-7.
16. SoraviaC, van derKliftH,BrundlerMA,Blouin JL,Wijnen J,HutterP, et al. Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 2003;121A:159-62.
17. Wagner DG, Gatalica Z, Lynch HT, Kohl S, Johansson SL, Lele SM. Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome. Int J Surg Pathol 2010;18:550-3.
18. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, et al. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004;74:1262-9.
19. Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2460-7.
20. Rosty C, Walsh MD, Lindor NM, Thibodeau S, Mundt E, Gallinger S, et al. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the Colon Cancer Family Registry. submitted 2013.
21. Bauer C, Ray A, Halstead-Nussloch B, Dekker R, Raymond V, Gruber S, et al. Hereditary prostate cancer as a feature of Lynch Syndrome. Fam Cancer 2011;10:37-42.
22. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-8.
23. Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10:793-8.
24. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutationnegative kindreds. Am J Hum Genet 2001;68:118-27.
25. Zhang YZ, Sheng JQ, Li SR, Zhang H. Clinical phenotype and prevalence of hereditary nonpolyposis colorectal cancer syndrome in Chinese population. World J Gastroenterol 2005;11:1481-8.
26. Goecke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert HK, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006;24:4285-92.
27. Maul JS, Warner NR, Kuwada SK, Burt RW, Cannon-Albright LA. Extracolonic cancers associated with hereditary nonpolyposis colorectal cancer in the Utah Population Database. Am J Gastroenterol 2006;101:1591-6.
28. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75:141-9.
29. Stupart DA, Goldberg PA, Algar U, Ramesar R. Cancer risk in a cohort of subjects carrying a single mismatch repair gene mutation. Fam Cancer 2009;8:519-23.
30. da SilvaFC, de Oliveira LP, Santos EM, Nakagawa WT, Aguiar Junior S, Valentin MD, et al. Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 2010;9:563-70.
31. Talseth-Palmer BA, McPhillips M, Groombridge C, Spigelman A, Scott RJ. MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer. Hered Cancer Clin Pract 2010;8:5.
32. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30:4409-15.
33. Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst 2012;104:1363-72.
34. Pande M, Wei C, Chen J, Amos CI, Lynch PM, Lu KH, et al. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry. Fam Cancer 2012;11: 441-7.
35. Barrow PJ, Ingham S, O'Hara C, Green K, McIntyre I, Lalloo F, et al. The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 2013;12:57-63.
36. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013;31:1713-8.
37. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812-23.
38. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
39. PubMed. Available from: http://www.ncbi.nlm.nih.gov/pubmed
40. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICGHNPCC). Dis Colon Rectum 1991;34:424-5.
41. Vasen HFA, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116:1453-6.
42. Umar A, Boland CR, Terdiman JP, Syngal S, Chapelle Adl, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
43. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011.
44. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
45. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003;27:1407-17.
46. Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133:48-56.
47. Carayol J, Khlat M, Maccario J, Bonaiti-Pellie C. Hereditary nonpolyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J Med Genet 2002;39:335-9.
48. Vieland VJ, Hodge SE. Inherent intractability of the ascertainment problem for pedigree data: a general likelihood framework. Am J Hum Genet 1995;56:33-43.
49. Win AK. Is prostate cancer a Lynch syndrome cancer? Asian J Androl 2013;15:588-9.
50. Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev 2010;19:258-64.
51. Tanaka Y, Zaman MS, Majid S, Liu J, Kawakami K, Shiina H, et al. Polymorphisms of MLH1 in benign prostatic hyperplasia and sporadic prostate cancer. Biochem Biophys Res Commun 2009;383: 440-4.
52. Hirata H, Hinoda Y, Kawamoto K, Kikuno N, Suehiro Y, Okayama N, et al. Mismatch repair geneMSH3polymorphismis associated with the risk of sporadic prostate cancer. J Urol 2008;179:2020-4.
53. Jafary F, Salehi M, Sedghi M, Nouri N, Jafary F, Sadeghi F, et al. Association between mismatch repair gene MSH3 codons 1036 and 222 polymorphisms and sporadic prostate cancer in the Iranian population. Asian Pac J Cancer Prev 2012;13:6055-7.
54. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
55. Rodriguez-Bigas M, Boland C, Hamilton S, Henson D, Srivastava S, Jass J, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.